Page 140 - FBL AR 2019-20

Fermenta Biotech Limited
Annual Report 2019-20

Notes to the Standalone financial statements for the year ended March 31, 2020

14 Investments (Current)
( H in Lakhs )
March 31, 2020 March 31, 2019
In Mutual funds at FVTPL*
Unquoted investments (Units of H10 each fully paid)
Union Capital Protection Oriented Fund - Series 7
Nil units (as at March 31, 2019 - 10,00,000) - 114.79
Total - 114.79

* Investments in mutual funds have been fair valued at the closing net asset value (NAV).
15 Trade receivables (unsecured)
( H in Lakhs )
March 31, 2020 March 31, 2019
Considered good 7,744.28 6,560.18
Credit Impaired 366.61 308.73
8,110.89 6,868.91
Less : Allowance for doubtful debts (Expected credit loss allowance) (366.61) (308.73)
Total 7,744.28 6,560.18
Movement in the expected credit loss allowance
Balance at the beginning of the year 308.73 1,033.63
Addition during the year 91.46 64.34
Written off during the year - (789.24)
Reversal during the year (33.58) -
Balance at the end of the year 366.61 308.73
16 Cash and cash equivalents
( H in Lakhs )
March 31, 2020 March 31, 2019
Balances with banks
In current accounts 673.10 1,133.87
In deposit accounts with original maturity for less than 3 months - 2,899.06
Cash on hand 4.31 3.34
Total 677.41 4,036.27
17 Bank balances other than cash and cash equivalents
( H in Lakhs )
March 31, 2020 March 31, 2019
Balances with banks
In Unpaid Dividend accounts 13.51 15.25
In escrow account 3.70 -
In deposit accounts with original maturity for more than 3 months but less than 12 months* 2,542.33 5,021.67
Total 2,559.54 5,036.92
*This includes deposits held under lien by bank against guarantees and other commitments amounting to H1,947.61 Lakhs (as at March 31,
2019: H560.69 Lakhs)

18 Loans (Current)
( H in Lakhs )
March 31, 2020 March 31, 2019
Unsecured, considered good
Inter corporate deposit # [Refer note 62 ]
D.K.Biopharma Private Limited 2,130.00 1,150.00
Loans to employees - 30.03
Others - 0.23
Total 2,130.00 1,180.26

# The inter-corporate deposits were granted to the entity for the purpose of its business.

138